(Total Views: 149)
Posted On: 04/11/2017 11:31:09 AM
Post# of 273336
(AXSM) here we go guys we are over $4 ,, this stock is what i call a once in a lifetime opp this stock should be at $20 right now not at laughable $4 .
5 Phase 3 Programs two of them targeting very large Markets with NO approved Drugs .
Marketcap: $90 Million
Cash: $50 Million
Price: $3.95
New Presentation
http://phx.corporate-ir.net/External.File?ite...==&t=1
AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions Phase 3 Phase 3 commenced March 2016. Interim analysis due 3Q 2017.
AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) Phase 3 Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 4Q 2017.
AXS-02 Chronic Low Back Pain Associated with Modic Changes Phase 3
AXS-05 Agitation in patients with Alzheimer’s disease (AD) Phase 2/3 Phase 2/3 to be initiated 2Q 2017.
AXS-05 STRIDE-1 Treatment resistant depression Phase 3 Phase 3 initiated March 2016. Top-line data due 1Q 2018.
5 Phase 3 Programs two of them targeting very large Markets with NO approved Drugs .
Marketcap: $90 Million
Cash: $50 Million
Price: $3.95
New Presentation
http://phx.corporate-ir.net/External.File?ite...==&t=1
AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions Phase 3 Phase 3 commenced March 2016. Interim analysis due 3Q 2017.
AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) Phase 3 Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 4Q 2017.
AXS-02 Chronic Low Back Pain Associated with Modic Changes Phase 3
AXS-05 Agitation in patients with Alzheimer’s disease (AD) Phase 2/3 Phase 2/3 to be initiated 2Q 2017.
AXS-05 STRIDE-1 Treatment resistant depression Phase 3 Phase 3 initiated March 2016. Top-line data due 1Q 2018.
(0)
(0)
